| Literature DB >> 30245684 |
Anna Ebbensgaard1,2, Hanne Mordhorst1, Frank M Aarestrup1, Egon B Hansen1.
Abstract
Bacterial resistance to classical antibiotics is emerging worldwide. The number of infections caused by multidrug resistant bacteria is increasing and becoming a serious threat for human health globally. In particular, Gram-negative pathogens including multidrug resistant Escherichia coli are of serious concern being resistant to the currently available antibiotics. All Gram-negative bacteria are enclosed by an outer membrane which acts as an additional protection barrier preventing the entry of toxic compounds including antibiotics and antimicrobial peptides (AMPs). In this study we report that the outer membrane component lipopolysaccharide (LPS) plays a crucial role for the antimicrobial susceptibility of E. coli BW25113 against the cationic AMPs Cap18, Cap11, Cap11-1-18m2, melittin, indolicidin, cecropin P1, cecropin B, and the polypeptide antibiotic colistin, whereas the outer membrane protease OmpT and the lipoprotein Lpp only play a minor role for the susceptibility against cationic AMPs. Increased susceptibility toward cationic AMPs was found for LPS deficient mutants of E. coli BW25113 harboring deletions in any of the genes required for the inner part of core-oligosaccharide of the LPS, waaC, waaE, waaF, waaG, and gmhA. In addition, our study demonstrates that the antimicrobial activity of Cap18, Cap11, Cap11-1-18m2, cecropin B, and cecropin P1 is not only dependent on the inner part of the core oligosaccharide, but also on the outer part and its sugar composition. Finally, we demonstrated that the antimicrobial activity of selected Cap18 derivatives harboring amino acid substitutions in the hydrophobic interface, are non-active against wild-type E. coli ATCC29522. By deleting waaC, waaE, waaF, or waaG the antimicrobial activity of the non-active derivatives can be partially or fully restored, suggesting a very close interplay between the LPS core oligosaccharide and the specific Cap18 derivative. Summarizing, this study implicates that the nature of the outer membrane component LPS has a big impact on the antimicrobial activity of cationic AMPs against E. coli. In particular, the inner as well as the outer part of the core oligosaccharide are important elements determining the antimicrobial susceptibility of E. coli against cationic AMPs.Entities:
Keywords: Cap18; Lpp; OmpT; antimicrobial peptides; lipopolysaccharide
Year: 2018 PMID: 30245684 PMCID: PMC6137088 DOI: 10.3389/fmicb.2018.02153
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1General structure of the cell envelope of Escherichia coli K-12. Schematic view of the cell envelope of E. coli K-12.
Figure 2Structure of the core-OS of Escherichia coli. (A) Structure of the inner region of the core-OS of the E. coli core types. Dashed lines indicate non-stoichiometric substitutions and the distinguishing modifications of different core types are indicated. (B) Structure of the outer region of the core-OS of the R1, R2, R3, R4, and K-12 core types. Glc, glucose; GlcN, glucosamine; Hep, L-glycero-D-manno-heptopyranose; Kdo, 3-deoxy-D-manno-oct-2-ulosonic acid; Rha, rhamonse; Gal, galactose; GlcNAc, N-acetylglucosamine; PEtN, phosphorylethanolamine.
Bacterial strains used in this study.
| Schmidt et al., | ||
| Hämmerling et al., | ||
| Schmidt et al., | ||
| Schmidt et al., | ||
| F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 wild-type strain used in the KEIO collection | Datsenko and Wanner, | |
| Baba et al., | ||
| Baba et al., | ||
| Baba et al., | ||
| Baba et al., | ||
| Baba et al., | ||
| Baba et al., | ||
| Baba et al., | ||
| Baba et al., | ||
| Baba et al., | ||
| Clinical isolate, Serotype O6, Biotype 1, control strain for antimicrobial susceptibility testing | ATCC strain collection | |
| Ebbensgaard et al., | ||
| Ebbensgaard et al., | ||
| Ebbensgaard et al., | ||
| Ebbensgaard et al., |
Cationic antimicrobial peptides used in this study: sequence, origin, and structure.
| Cap18 | GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY | Mammalian, rabbit, neutrophils | α-helical |
| Cap11 | GLRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQIPYPCRI | Mammalian, guinea pig, neutrophils | α-helical |
| Cap11-1-18m2 | KLRKLFRKLLKLIRKLLR | Truncated derivative of Cap11 | |
| Cecropin P1 | SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | Mammalian, pig, small intestine | α-helical |
| Cecropin B | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKALG-NH2 | Insects, giant silk moth, pupae | α-helical |
| Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 | Insects, honey bee | α-helical |
| Indolicidin | ILPWKWPWWPWR-NH2 | Mammalian, bovine neutrophils | extended |
Antimicrobial activity of Cap18 derivatives against E. coli ATCC25922 LPS mutants and other Enterobacteriaceae.
| Cap18-original | 4–8 | 2–4 | 4 | 2–4 | 4 | 4–8 | 2–4 |
| L17K | ≥64 | 8 | 8 | 8 | 8 | 16 | ≥64 |
| I20E | ≥64 | 4 | 4 | 4 | 8 | 8 | 32 |
| I24G | ≥64 | 8 | 8 | 8 | 8 | 8–16 | 32 |
| L27P | ≥64 | 8 | 4 | 4 | 4 | 8 | 32 |
| I24N | ≥64 | 8 | 16 | 8 | 16 | 32 | ≥64 |
| I20N | ≥64 | 16 | 16 | 8 | 16 | 8–16 | ≥64 |
| I13R | ≥64 | 32 | ≥64 | 16 | 8 | 16–32 | 32–64 |
| I24D | ≥64 | 16 | 16 | 16 | ≥64 | ≥64 | ≥64 |
| I13P | ≥64 | 32 | 32 | 16 | 32 | 16–32 | ≥64 |
| I24D | ≥64 | 16 | 16 | 16 | ≥64 | ≥64 | ≥64 |
| I13D | ≥64 | ≥64 | ≥64 | ≥64 | ≥64 | ≥64 | ≥64 |
| L17D | ≥64 | ≥64 | ≥64 | ≥64 | ≥64 | ≥64 | ≥64 |
| L17P | ≥64 | ≥64 | ≥64 | ≥64 | ≥64 | ≥64 | ≥64 |
| I13F | 4 | 2 | 2 | 2 | 2 | 4 | 2 |
| I13H | 4 | 2 | 2 | 2 | 2 | 4 | 8–16 |
| K16D | 4 | 2 | 8 | 2 | 4 | 4 | 4 |
| L6P | 8 | 4 | 8 | 4 | 4 | 8 | 64 |
| I13M | 8 | 4 | 8 | 4 | 4 | 8 | 4 |
| K16C | 8 | 4 | 8 | 4 | 8 | 8–16 | 8–16 |
| K18P | 8 | 2 | 4 | 4 | 4 | 4 | 32 |
| G26T | 8 | 4 | 4 | 4 | 4 | 4–8 | 2–4 |
Data are collected as minimal inhibitory concentrations (MICs) according to the Clinical and Laboratory Standards Institute (CLSI) and expressed in μg/ml. All MIC determinations were carried out in in triplicates.
Susceptibility of E. coli BW25113 mutants deficient in outer membrane to cationic antimicrobial peptides.
| 4–8 | 8 | 8–16 | 16–32 | 32 | 16–32 | 16–32 | 0.125–0.25 | |
| 4 | 8 | 8 | 4 | 16 | 8 | 8 | 0.063–0.125 | |
| 4 | 8 | 8 | 4 | 16 | 8 | 8 | 0.063–0.125 | |
| 4 | 8 | 8 | 4 | 16 | 4 | 4 | 0.063 | |
| 4 | 8 | 8 | 4 | 16 | 16 | 16 | 0.063–0.125 | |
| 4–8 | 8 | 8 | 2 | 16 | 4–8 | 4–8 | 0.063 | |
| 4–8 | 4–8 | 8 | 32 | 32 | 16 | 16 | 0.125–0.25 | |
| 2–4 | 8 | 8–16 | n.d. | n.d. | n.d. | 16 | 0.063–0.125 | |
| 4–8 | 8–16 | n.d. | 4 | 32 | 16–32 | 32 | 0.125–0.25 | |
| 4–8 | 8–16 | n.d. | 16–32 | 32 | 32 | 32–64 | 0.125–0.25 |
Data are collected as minimal inhibitory concentrations (MICs) according to the Clinical and Laboratory Standards Institute (CLSI) and expressed in μg/ml. All MIC determinations were carried out in duplicates
or in triplicates.
n.d., not determined.
Antimicrobial activity of selected antimicrobial peptides in Escherichia coli with different LPS core types.
| 4–8 | 8 | 16–32 | 16–32 | 32 | 16–32 | 16–32 | |
| 4 | 16 | 32 | 16 | ≥32 | 32 | 32 | |
| 4 | 8 | 16–32 | 32 | ≥32 | 32 | 16–32 | |
| 4–8 | 16 | ≥32 | 32 | ≥32 | 32 | 32 | |
| 2–4 | 4–8 | 8–16 | 4 | 8–16 | 16–32 | 16 | |
| 4 | 16 | 32 | 16 | 32 | 32 | 32 | |
Data are collected as minimal inhibitory concentrations (MICs) according to the Clinical and Laboratory Standards Institute (CLSI) and expressed in μg/ml. All MIC determinations were carried out in triplicates.
Cap18 derivatives: amino acid sequence, purity, solvent, manufacturer.
| Cap18-original | GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY | ≥89.5% | DMSO | Genscript |
| L6P | GLRKR | 99.9% | DMSO | Genscript |
| I13D | GLRKRLRKFRNK | 96.59% | DMSO | Peptide 2.0 |
| I13P | GLRKRLRKFRNK | 98.67% | DMSO | Peptide 2.0 |
| I13R | GLRKRLRKFRNK | 95.97% | DMSO | Peptide 2.0 |
| I13F | GLRKRLRKFRNK | 100% | DMSO | Peptide 2.0 |
| I13H | GLRKRLRKFRNK | 97.8% | DMSO | Genscript |
| I13M | GLRKRLRKFRNK | 100% | DMSO | Peptide 2.0 |
| K16C | GLRKRLRKFRNKIKE | 95.8% | DMSO | Genscript |
| K16D | GLRKRLRKFRNKIKE | 99.84% | DMSO | Peptide 2.0 |
| L17D | GLRKRLRKFRNKIKEK | 97.46% | DMSO | Peptide 2.0 |
| L17K | GLRKRLRKFRNKIKEK | 96.84% | DMSO | Peptide 2.0 |
| L17P | GLRKRLRKFRNKIKEK | 96.26% | DMSO | Peptide 2.0 |
| K18P | GLRKRLRKFRNKIKEKL | 99.32% | DMSO | Peptide 2.0 |
| I20E | GLRKRLRKFRNKIKEKLKK | 99.72% | DMSO | Peptide 2.0 |
| I20N | GLRKRLRKFRNKIKEKLKK | 96.95% | DMSO | Peptide 2.0 |
| I24D | GLRKRLRKFRNKIKEKLKKIGQK | 98.99% | DMSO | Peptide 2.0 |
| I24G | GLRKRLRKFRNKIKEKLKKIGQK | 96.2% | DMSO | Genscript |
| I24N | GLRKRLRKFRNKIKEKLKKIGQK | 99.78% | DMSO | Peptide 2.0 |
| G26T | GLRKRLRKFRNKIKEKLKKIGQKIQ | 95.05% | DMSO | Peptide 2.0 |
| L27P | GLRKRLRKFRNKIKEKLKKIGQKIQG | 97.94% | DMSO | Peptide 2.0 |
Amino acid substitution is highlighted in bold.
Figure 3Predicted structure of Cap18. The structure of Cap18 was predicted using I-Tasser (Roy et al., 2010) and visualized by CCP4 software (McNicholas et al., 2011). The predicted α-helix is highlighted in red. Hydrophobic residues of the α-helix are shown in green. (A) View along helix axis, (B) view from N- to C-terminal, (C) view form C- to N-terminal.